Skip to contentN
Neogenomics Inc
N
NEONeogenomics Inc Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$190.17M$190.17Mderived+10.6% vs Q4 2024 Net Income-$9.88M-$9.88MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Neogenomics Inc · CIK 1077183 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$83,343,000+7.9% Operating Incomederived-$13,414,000N/M Operating Cash Flowderived$1,343,000−86.3% Free Cash Flowderived-$6,528,000N/M Margins · derivedGross margin43.8%−1.1 pt vs Q4 2024
Operating margin-7.1%+3.6 pt vs Q4 2024
Net margin-5.2%+3.7 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 17, 2026 · 48 d after period end